Viridian reports Q2 2026 results as Lumvoa launch begins in the U.S.
The FDA-approved thyroid eye disease drug started shipping doses in July, while Viridian keeps a Q1 2027 BLA target for follow-on candidate elegrobart.
SEC filing
Latest
1 story
Sign in